Core Insights - Ribo Life Science Co., Ltd. has been invited to present at the RNA Leaders Europe Conference on March 19, highlighting its advancements in ex-hepatic delivery systems for siRNA [1] Group 1: Company Developments - Ribo has achieved significant success with its RiboGalSTAR™ platform, which targets specific liver genes and has seven clinical programs along with two major global collaborations and licensing agreements valued at over $6 billion [1] - The company is advancing its proprietary RiboPepSTAR™ technology for targeted siRNA delivery to multiple critical organs beyond the liver [1] Group 2: Research and Development - Preclinical data indicates effective renal delivery of siRNA, showing specific uptake in proximal tubules and mRNA level reduction across various species, including rodents and non-human primates [1] - In addition to renal applications, Ribo is developing preclinical candidates targeting cardiac disorders, adipose tissue, muscle, and the central nervous system [1]
Ribo presentará datos sobre la administración ex-hepática en la Conferencia RNA Leaders Europe
Prnewswire·2026-03-17 03:00